Literature DB >> 26202573

Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma.

Andreas Thorstenson1,2,3, Ulrika Harmenberg4, Per Lindblad5, Börje Ljungberg1, Sven Lundstam6.   

Abstract

OBJECTIVE: The aim of this population-based study was to evaluate the impact of quality indicators on the adherence to guidelines for renal cell carcinoma (RCC).
MATERIAL AND METHODS: Since 2005, virtually all patients with newly diagnosed RCC in Sweden have been registered in the National Swedish Kidney Cancer Register (NSKCR). The register contains information on histopathology, nuclear grade, clinical stage, preoperative work-up, treatment, recurrence and survival. In addition, a number of quality indicators have been measured in the register aiming to increase the quality of care. The quality indicators are: the coverage of the register, histology reports, preoperative chest computed tomography (CT), partial nephrectomy, laparoscopic surgery, centralization to high-volume hospitals and waiting times.
RESULTS: A total of 8556 patients with diagnosed RCC were registered from 2005 to 2013 (99% coverage). In 2013, 99% of the histopathology reports were standardized. The number of patients with preoperatively chest CT increased from 59% in 2005 to 89% in 2013. The proportion of patients with RCC T1aN0M0 who underwent partial nephrectomy increased from 22% in 2005 to 56% in 2013. Similarly, laparoscopic radical nephrectomies increased from 6% in 2005 to 24% in 2013. The median tumour size at detection decreased from 60 mm in 2005 to 55 mm in 2013. The proportion of patients who were incidentally detected increased from 43% in 2005 to 55% in 2013.
CONCLUSIONS: The data show an improved adherence to the guidelines for RCC as measured by quality indicators and a steady process of earlier detection of patients with RCC.

Entities:  

Keywords:  Population-based; Sweden; quality indicators; renal cell carcinoma; surgery; tumour size; tumour type

Mesh:

Year:  2015        PMID: 26202573     DOI: 10.3109/21681805.2015.1059882

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  6 in total

1.  Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.

Authors:  Keith A Lawson; Olli Saarela; Zhihui Liu; Luke T Lavallée; Rodney H Breau; Lori Wood; Michael A S Jewett; Anil Kapoor; Simon Tanguay; Ronald B Moore; Ricardo Rendon; Frederic Pouliot; Peter C Black; Jun Kawakami; Darrel Drachenberg; Antonio Finelli
Journal:  Can Urol Assoc J       Date:  2017-08       Impact factor: 1.862

2.  Variability in surgical management of kidney cancer between urban and rural hospitals in Queensland, Australia: a population-based analysis.

Authors:  Megan K Forbes; Evan P Owens; Simon T Wood; Glenda C Gobe; Robert J Ellis
Journal:  Transl Androl Urol       Date:  2020-06

3.  Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.

Authors:  Saeed Dabestani; Andreas Thorstenson; Per Lindblad; Ulrika Harmenberg; Börje Ljungberg; Sven Lundstam
Journal:  World J Urol       Date:  2016-02-05       Impact factor: 4.226

4.  Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.

Authors:  Kari Hemminki; Asta Försti; Akseli Hemminki; Börje Ljungberg; Otto Hemminki
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

5.  Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden.

Authors:  Andreas Thorstenson; Ulrika Harmenberg; Per Lindblad; Benny Holmström; Sven Lundstam; Börje Ljungberg
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

6.  A psychometric evaluation of the Functional assessment of cancer therapy-kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure.

Authors:  Andreas Karlsson Rosenblad; Pernilla Sundqvist; Bodil Westman; Börje Ljungberg
Journal:  Qual Life Res       Date:  2021-04-12       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.